Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2025-12-30 @ 12:01 PM
Study NCT ID:
NCT01050634
Status:
COMPLETED
Last Update Posted:
2010-07-23
First Post:
2010-01-13
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)
Sponsor:
Pfizer
Organization:
Study Overview
Official Title:
Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) a Non-interventional Trial With Aromasin®
Status:
COMPLETED
Status Verified Date:
2010-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FAST
Brief Summary:
Quality of life under therapy with Aromasin® (exemestane) according to IBCSG (International Breast Cancer Study Group) questionnaire.
Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
Deeper knowledge of Adverse Events during routine administration.
Change of the endometrium after switching from tamoxifen to Aromasin® (exemestane).
Deeper knowledge of Adverse Events during routine administration.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: